In vivo, oral administration of PDTC inhibits tumor growth, migration and angiogenesis of breast cancer via inhibiting autocrine and paracrine effects of VEGF through the reduction of NF-κB activation and VEGF expression in female mice [23]. The gene discussed is NFKB1; the disease is neoplasm.